Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
71 studies found for:    vismodegib
Show Display Options
Rank Status Study
1 Completed Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas
Conditions: Basal Cell Nevus Syndrome;   Gorlin's Syndrome
Interventions: Drug: Vismodegib;   Drug: Aminolevulinic acid %20 topical solution
2 Recruiting Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas
Condition: Basal Cell Carcinoma
Intervention: Drug: Vismodegib
3 Completed
Has Results
Vismodegib for Treatment of Basal Cell Carcinoma
Condition: Basal Cell Carcinoma
Interventions: Drug: Vismodegib;   Drug: Placebo
4 Completed Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention
Condition: Basal Cell Carcinomas
Interventions: Drug: Vismodegib;   Drug: Placebo
5 Active, not recruiting A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
Condition: Prostate Cancer
Intervention: Drug: Vismodegib
6 Terminated Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia
Conditions: Diffuse Large B-cell Lymphoma;   "Indolent" Non-hodgkin Lymphoma;   Primary Central Nervous System Lymphoma;   Chronic Lymphocytic Leukemia
Intervention: Drug: Vismodegib
7 Active, not recruiting A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors
Condition: Keratocystic Odontogenic Tumor
Intervention: Drug: vismodegib
8 Recruiting Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
Conditions: Locally Advanced Basal Cell Carcinoma;   Skin Cancer;   Cutaneous Malignancy
Interventions: Drug: Vismodegib;   Radiation: Radiation therapy
9 Recruiting To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell Carcinoma
Condition: Carcinoma, Basal Cell
Interventions: Drug: Vismodegib;   Radiation: Radiotherapy
10 Terminated
Has Results
Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma
Condition: Pontine Glioma
Intervention: Drug: Vismodegib
11 Completed
Has Results
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission
Condition: Ovarian Cancer
Interventions: Drug: Vismodegib 150 mg;   Drug: Placebo to vismodegib
12 Completed
Has Results
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
Condition: Basal Cell Carcinoma
Intervention: Drug: Vismodegib
13 Completed
Has Results
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma
Condition: Basal Cell Carcinoma
Intervention: Drug: Vismodegib 150 mg
14 Active, not recruiting
Has Results
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
Condition: Basal Cell Carcinoma
Interventions: Drug: Vismodegib;   Drug: Placebo
15 Completed
Has Results
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
Condition: Recurrent Childhood Medulloblastoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Vismodegib
16 Active, not recruiting Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)
Condition: Basal Cell Carcinoma
Intervention: Drug: ERIVEDGE
17 Recruiting A Safety and Tolerability Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Pirfenidone;   Drug: Vismodegib
18 Completed
Has Results
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
Condition: Adult Medulloblastoma
Interventions: Other: Pharmacological Study;   Drug: Vismodegib
19 Recruiting Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway
Conditions: Histologically Confirmed Medulloblastoma;   Activation of the Sonic Hedgehog (SHH) Pathway
Interventions: Drug: vismodegib;   Drug: Temozolomide
20 Active, not recruiting Vismodegib in Treating Patients With Basal Cell Carcinoma
Conditions: Basal Cell Carcinoma of the Skin;   Recurrent Skin Cancer
Interventions: Drug: vismodegib;   Procedure: Mohs surgery

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.